Cargando…

Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma

IMPORTANCE: Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment and are now standard of care. Although sex is associated with immune function and immune-related diseases, the interaction between sex and ICIs is understudied. OBJECTIVE: To examine whether cancer immunotherapy e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Se Ryeong, Nikita, Nikita, Banks, Joshua, Keith, Scott W., Johnson, Jennifer M., Wilson, Melissa, Lu-Yao, Grace
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640892/ https://www.ncbi.nlm.nih.gov/pubmed/34854905 http://dx.doi.org/10.1001/jamanetworkopen.2021.36823

Ejemplares similares

Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study
por: Nikita, Nikita, et al.
Publicado: (2022)

Understanding the role of sex on outcomes for the cancer patient undergoing treatment with immune checkpoint inhibitors: a scoping review protocol
por: Shaver, Amy L, et al.
Publicado: (2022)

Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults
por: Schonfeld, Sara J., et al.
Publicado: (2022)

The Effects of Physical Activity on Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors: A Scoping Review
por: Shaver, Amy L., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis
por: Chang, Ching-Yuan, et al.
Publicado: (2020)

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors
por: Waninger, Jessica J., et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gallbladder With a Mass
por: Fernandes, Nayson L, et al.
Publicado: (2020)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
por: Gowen, Michael F., et al.
Publicado: (2018)

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma
por: Akturk, Halis Kaan, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer
por: Zhuo, Na, et al.
Publicado: (2022)

Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
por: Subedi, Ananta, et al.
Publicado: (2020)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non–Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
por: Everest, Louis, et al.
Publicado: (2019)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors
por: Hsu, Sanford P. C., et al.
Publicado: (2020)

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors
por: Hsiehchen, David, et al.
Publicado: (2019)

Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
por: Van Buren, Inga, et al.
Publicado: (2023)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
por: Rosner, Samuel, et al.
Publicado: (2020)

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
por: Bomze, David, et al.
Publicado: (2020)

Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis
por: Jácome, Alexandre A., et al.
Publicado: (2021)

Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis
por: Farooq, Muhammad Zain, et al.
Publicado: (2022)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
por: Olbryt, Magdalena, et al.
Publicado: (2020)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma
por: Melin, Audrey, et al.
Publicado: (2022)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023)

Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
por: Travis, Roman L., et al.
Publicado: (2020)

Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors
por: Chong, Pei Pei, et al.
Publicado: (2022)

Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition
por: Kudura, Ken, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vmj9kt7mhf93o882neup3p58jj